Latest Information
January 30th, 2018
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared with everolimus, according to a study published in the Journal of Clinical Oncology.1
December 15th, 2017
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.
October 13th, 2017
Cancer-specific mortality among patients who undergo surgery for non-metastatic renal cell carcinoma (RCC) vary according to histologic subtypes of the malignancy, new findings suggest.
Print this page Tell A Friend Add to Favorites

RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk

October 13, 2017

Jody A. Charnow, Editor

Cancer-specific mortality among patients who undergo surgery for non-metastatic renal cell carcinoma (RCC) vary according to histologic subtypes of the malignancy, new findings suggest.

Compared with clear cell RCC, papillary RCC is associated with a significant 24% reduced risk of cancer-specific mortality, and papillary RCC type 1 is associated with a significant 69% decreased risk of death, investigators reported online in PLoS One. The investigators found no difference in cancer-specific mortality between papillary RCC type 2 and clear cell RCC.

As a result of the study's findings, the authors concluded there is an urgent need to consider histopathologic entities and their subtypes when deciding on follow-up or targeted therapy for RCC patients.

The study, by Nina Wagener, MD, of Mannheim Medical Center in Mannheim, Germany, and colleagues, included 7543 European and North American patients who underwent radical or partial nephrectomy for RCC. The group included 1943 patients with papillary RCC and 5600 with clear cell RCC. The median follow-up was 64.6 months.

Related Articles

Reference

Wagener N, Edelmann D, Benner A, et al. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. PLoS One 2017 Sep 21;12(9):e0184173. doi: 10.1371/journal.pone.0184173

Filed Under: Uncategorized